These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11975794)

  • 41. Role of aquaporin-2 water channels in urinary concentration and dilution defects.
    Martin PY; Schrier RW
    Kidney Int Suppl; 1998 Apr; 65():S57-62. PubMed ID: 9551433
    [No Abstract]   [Full Text] [Related]  

  • 42. Role of aquaporins in renal water handling: physiology and pathophysiology.
    van Os CH; Deen PM
    Nephrol Dial Transplant; 1998 Jul; 13(7):1645-51. PubMed ID: 9681706
    [No Abstract]   [Full Text] [Related]  

  • 43. Role of vasopressin V2 receptor in acute regulation of aquaporin-2.
    Hayashi M; Sasaki S; Tsuganezawa H; Monkawa T; Kitajima W; Konishi K; Fushimi K; Marumo F; Saruta T
    Kidney Blood Press Res; 1996; 19(1):32-7. PubMed ID: 8818115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus.
    Zhang Y; Peti-Peterdi J; Müller CE; Carlson NG; Baqi Y; Strasburg DL; Heiney KM; Villanueva K; Kohan DE; Kishore BK
    J Am Soc Nephrol; 2015 Dec; 26(12):2978-87. PubMed ID: 25855780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Disordered water channel expression and distribution in acquired nephrogenic diabetes insipidus.
    Marples D; Frøkiaer J; Knepper MA; Nielsen S
    Proc Assoc Am Physicians; 1998; 110(5):401-6. PubMed ID: 9756090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
    Serradeil-Le Gal C
    Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Water channels in health and disease.
    Berl T
    Kidney Int; 1998 May; 53(5):1417-8. PubMed ID: 9573561
    [No Abstract]   [Full Text] [Related]  

  • 48. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
    Mouillac B; Mendre C
    Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Nephrogenic diabetes insipidus].
    Evrard A; Lefebvre J; Vantyghem M
    Ann Endocrinol (Paris); 1999 Dec; 60(6):457-64. PubMed ID: 10617799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Body water homeostasis: clinical disorders of urinary dilution and concentration.
    Schrier RW
    J Am Soc Nephrol; 2006 Jul; 17(7):1820-32. PubMed ID: 16738014
    [No Abstract]   [Full Text] [Related]  

  • 51. The molecular basis of nephrogenic diabetes insipidus.
    Oksche A; Rosenthal W
    J Mol Med (Berl); 1998 Apr; 76(5):326-37. PubMed ID: 9587067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular mechanisms of clinical concentrating and diluting disorders.
    Schrier RW
    Prog Brain Res; 2008; 170():539-50. PubMed ID: 18655907
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Vasopressin V2 receptor antagonists: pharmacological properties and clinical implications].
    Abassi Z; Bishara B; Yaccob A; Hoffman A
    Harefuah; 2005 Dec; 144(12):875-80, 909. PubMed ID: 16400790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vasopressin receptor mutations causing nephrogenic diabetes insipidus.
    Bichet DG; Turner M; Morin D
    Proc Assoc Am Physicians; 1998; 110(5):387-94. PubMed ID: 9756088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lixivaptan: a novel vasopressin receptor antagonist.
    Ku E; Nobakht N; Campese VM
    Expert Opin Investig Drugs; 2009 May; 18(5):657-62. PubMed ID: 19379124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aquaporins in kidney pathophysiology.
    Noda Y; Sohara E; Ohta E; Sasaki S
    Nat Rev Nephrol; 2010 Mar; 6(3):168-78. PubMed ID: 20101255
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Nephrogenic diabetes insipidus associated with mutations of vasopressin V2 receptors and aquaporin-2].
    Ishikawa SE
    Nihon Rinsho; 2002 Feb; 60(2):350-5. PubMed ID: 11857925
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inherited secondary nephrogenic diabetes insipidus: concentrating on humans.
    Bockenhauer D; Bichet DG
    Am J Physiol Renal Physiol; 2013 Apr; 304(8):F1037-42. PubMed ID: 23364801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y; Miura K; Iwao H
    J Pharmacol Sci; 2014; 124(1):1-6. PubMed ID: 24401675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus.
    Ando F; Uchida S
    Clin Exp Nephrol; 2018 Jun; 22(3):501-507. PubMed ID: 29478202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.